SynthesisHeart failure reviews2025
Urine sodium-guided diuresis in acute heart failure: a systematic review and meta-analysis of efficacy and safety.
Synthesis in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute heart failure (AHF) is a leading cause of hospitalization among older adults and is associated with high rates of rehospitalization and mortality. Intravenous diuretics are the cornerstone of treatment, but diuretic response is highly variable. Spot urine sodium measurement has emerged as a novel tool to guide diuretic titration. We aim to evaluate the efficacy and safety of urine sodium-guided diuresis (USGD) compared to standard of care (SOC) in AHF.
methodsOnline databases were searched. Outcomes included 48-hour natriuresis, 48-hour diuresis, 48-hour weight loss, length of stay (LOS), all-cause mortality, heart failure (HF) rehospitalization, acute kidney injury (AKI), hypotension and hypokalemia. These were reported as risk ratio (RR) for categorical outcomes and mean difference (MD) for continuous outcomes with a random effects model using 95% confidence intervals (CI).
resultsFive studies with 920 patients were selected. USGD was associated with an increased 48-hour natriuresis (MD = 139.13 mmol [95% CI: 4.84, 273.43], p = 0.047) and diuresis (MD = 1.12 L [95% CI: 0.09, 2.15], p = 0.043) and a lower risk of AKI (RR = 0.51 [95% CI: 0.27, 0.97], p = 0.039). There were no significant differences in 48-hour weight loss (MD = 0.45 kg), LOS (MD=-0.38 days), all-cause mortality (RR = 0.93), HF rehospitalization (RR = 0.91), hypotension (RR = 1.06), or hypokalemia (RR = 0.97).
conclusionUSGD was associated with an increased 48-hour natriuresis and diuresis and a lower risk of AKI compared to SOC in AHF. However, there was no difference in 48-hour weight loss, LOS, all-cause mortality, HF rehospitalization, hypotension, or hypokalemia. While USGD improved short-term natriuresis and renal safety endpoints, further randomized trials are needed to determine optimal urine sodium thresholds and long-term outcomes.
Indexed as
Identifiers
41389092What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.